One of the key milestones in my awareness campaigns occurred when I featured as a guest blogger for one of the biggest cancer ‘support’ organisations in the world – Macmillan.
The aim of the blog ‘Sorry I’m not in service’ was actually to highlight the consequences of cancer and its treatment (a Macmillan Campaign message), and to a certain extent to highlight the conflict that can often exist between work and cancer. However, it was also a fantastic opportunity for me to grab the interest of the general population with the word ‘Neuroendocrine’. The response was amazing and on twitter it was one of Macmillan’s most retweeted posts over that period. The Macmillan Facebook post was also very popular and still rising with around 500 likes and around 40 shares so far.
There are some great comments on the post and the one which stuck out most is now the title of this blog article. I’ve always thought the ‘anatomy’ factor was a strong awareness message for Neuroendocrine Cancer and I outlined this in an article I wrote last year entitled ‘The Human Anatomy of Neuroendocrine Cancer’. There are not many cancers that have the anatomical reach of Neuroendocrine Cancer – the ‘suckers’ can indeed get everywhere!
Although there are common areas for Neuroendocrine Cancer to pop up, there are also many rare locations. I was, therefore, both astonished and delighted when the Macmillan Facebook post brought together two people from UK diagnosed with a NET of the nasal cavity, an extremely rare location for any cancer.
Why is the potential distribution of NETs so wide? Neuroendocrine Cancer is nearly always formed in the diffuse neuroendocrine system, which is made up of neuroendocrine cells found in the respiratory and digestive tracts. The respiratory tract includes the bronchial tubes and lungs. The digestive tract starts at the mouth and ends at the rectum. Neuroendocrine cells are also found in the endocrine glands, such as the adrenal glands, pancreas, thyroid, parathyroid, and pituitary. These cells are also found in the ovaries and the testes. However, these ‘little suckers’ have a propensity to spread (metastasize) and can end up in even more obscure sites throughout the body. When you carry out a bit of light research in reputable areas plus taking into account their metastatic tendencies, you end up with a list like this:
Small intestine (small bowel)
Lung (including the pulmonary pleura)
Large intestine (large bowel or colon)
Eye – including Retro-orbital (situated or occurring behind the orbit) and the choroid (vascular structure supplying the outer)
Mesentery (keeps the small intestine in place against the abdominal wall)
Peritoneum (lining of the abdominal cavity)
Retroperitoneum (behind the Peritoneum)
Skin (Merkel cell)
Bones in general
Sacrum – the large, triangular bone at the base of the spine
Lymph Nodes – mainly in the area of the Mesentery, Peritoneum, Retroperitoneum, Chest Wall; but also in distant locations such as axillary (armpit) and supraclavicular (collar-bone area)
Did I miss any? Feel free to add!
Subscribe to my newsletter
Top 10 Posts & Pages in the last 48 hours (auto updates)
Thanks for reading.
Sign up for my newsletters – Click Here
Please Share this post for Neuroendocrine Cancer awareness and to help another patient
Curtis Crump: Credit MD Anderson Cancer Center Curtis Crump has an amazing story to tell. Given 6 months to live, he refused to accept that
Certain popular ideas about how cancer starts and spreads – though scientifically wrong, can seem to make sense, especially when those ideas are rooted in
Survival Outcomes in Metastatic Gastroenteropancreatic Neuroendocrine Tumor Patients receiving Concomitant 225Ac-DOTATATE Targeted Alpha Therapy and Capecitabine: A Real-world Scenario Management Based Long-term Outcome Study
Introduction I’ve written about both 225Ac-DOTATATE targeted alpha therapy (TAT) and Capecitabine before but never as a concomitant pair (combo). So, when this Indian study
It’s hard to be positive when you don’t know how you’re doing. The only way to know how you’re doing is to get professional surveillance.
Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors: A Nonrandomized Clinical Trial
Background Well differentiated NETs have been described as an “immunological desert” in recent years mainly due to the poor response rate data coming out of
Every July, I think back to my diagnosis of advanced Neuroendocrine Cancer in 2010. I guess one of the reasons I do this is to
The COVID-19 pandemic filled our vocabularies with more medical terms than most of us would ever hear about, but some were familiar. It soon became